Use of Machine‐Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension
Open Access
- 1 April 2026
- journal article
- research article
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (2) , e70294
Abstract
Clinical worsening events are increasingly recognized as a meaningful outcome in pulmonary arterial hypertension (PAH). We applied machine‐learning models to real‐world data to identify clinical features that may predict clinical worsening events in PAH. Data were obtained retrospectively from the electronic health records of adults diagnosed with PAH at Mayo Clinic locations (January 2015–December 2019). Machine‐learning LASSO regularized logistic regression models were developed to analyze the association between 100 clinical features and occurrence of clinical worsening events. In total, 455 patients were included (mean age 62.1 years; 59.3% female). Of these, 232 (51.0%) experienced a clinical worsening event after a median (quartile 1, quartile 3) of 10.9 (4.1, 21.4) months. The best‐performing model had an area under the curve of 0.78, sensitivity of 78%, and specificity of 59%. The model identified 11 clinical features associated with clinical worsening events in PAH with a non‐zero coefficient: baseline age, body mass index (BMI), creatinine level, red cell (erythrocyte) distribution width (RDW), mean pulmonary arterial pressure, pulmonary vascular resistance, sodium concentration, and QT interval, along with dyspnea, number of clinic visits, and other forms of heart disease within a 1‐month window before a clinical worsening event. Baseline RDW and BMI, and number of clinic visits within the 1‐month window were statistically significantly associated with clinical worsening events. Our study used machine‐learning models to identify clinical features associated with risk of clinical worsening events in PAH. Automation of risk prediction could lead to earlier therapeutic intervention to optimize patient outcomes.Keywords
Funding Information
- Johnson and Johnson
This publication has 26 references indexed in Scilit:
- Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial HypertensionJACC: Cardiovascular Imaging, 2021
- Prognostic impact of red blood cell distribution width in pulmonary hypertension patientsMedicine, 2020
- Predicting Survival in Patients With Pulmonary Arterial HypertensionChest, 2019
- Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomesClinicoEconomics and Outcomes Research, 2017
- A simple hemodynamic parameter to predict clinical worsening in pulmonary arterial hypertensionJournal of Critical Care, 2017
- Early Decline in Six-Minute Walk Distance from the Time of Diagnosis Predicts Clinical Worsening in Pulmonary Arterial HypertensionRespiration, 2015
- Pulmonary arterial hypertensionOrphanet Journal of Rare Diseases, 2013
- Heart Rate Recovery Predicts Clinical Worsening in Patients with Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertensionHeart, 2011
- Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension††Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.The American Journal of Cardiology, 2009